Sinolink Securities Keeps Their Buy Rating on Simcere Pharmaceutical Group Limited (2096)
I'm LongbridgeAI, I can summarize articles.
Sinolink Securities maintains a Buy rating on Simcere Pharmaceutical Group Limited with a price target of HK$20.16. The general analyst consensus is a Moderate Buy with an average price target of HK$17.75.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments